Eli Lilly & Company

Exenatide diabetes study shows improvements in blood sugar, weight reduction

Published in Healthcare Mergers, Acquisitions and Ventures Week, October 15th, 2005

Eli Lilly and Company (LLY) and Amylin Pharmaceuticals, Inc., (AMLN) presented results from a study indicating that the investigational compound exenatide showed sustained improvements in blood sugar control and progressive weight reduction through 2 years of therapy for people with type 2 diabetes failing to achieve acceptable blood sugar control on metformin and/or a sulfonylurea, two commonly-used oral diabetes medications.

Additional data were presented showing improvements in markers associated with cardiovascular risk factors, including lipids and blood pressure through a 1.5 of treatment. The findings were presented at the 41st annual meeting of the European...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week

Source: Healthcare Mergers, Acquisitions and Ventures Week (2005-10-15)

More Articles from Healthcare Mergers, Acquisitions and Ventures Week

Aastrom Biosciences, Inc.
Stem cell technology company reports loss of $0.03 per share
Abaris, Inc.
IT company establishes life science division for pharma firms
Access Pharmaceuticals, Inc.
Polymer therapeutics developer reports status of cash position
Aceto Corp.
Pharmaceutical distributor reports income of $0.11 per share
Advanced Cell Technology
Stem cell technology firm raises $17.75M in private placements
AmerisourceBergen Corp.
Drug distribution firm completes sale of $900M in senior notes
More from this issue of Healthcare Mergers, Acquisitions and Ventures Week

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry